These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 19797729)
1. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E; Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729 [TBL] [Abstract][Full Text] [Related]
2. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases. Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791 [TBL] [Abstract][Full Text] [Related]
4. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352 [TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430 [TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105 [TBL] [Abstract][Full Text] [Related]
7. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486 [TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255 [TBL] [Abstract][Full Text] [Related]
9. Mutation in TET2 in myeloid cancers. Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426 [TBL] [Abstract][Full Text] [Related]
10. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Gelsi-Boyer V; Cervera N; Bertucci F; Brecqueville M; Finetti P; Murati A; Arnoulet C; Mozziconacci MJ; Mills KI; Cross NC; Vey N; Birnbaum D Haematologica; 2013 Apr; 98(4):576-83. PubMed ID: 23065512 [TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia. Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757 [No Abstract] [Full Text] [Related]
12. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856 [TBL] [Abstract][Full Text] [Related]
13. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470 [TBL] [Abstract][Full Text] [Related]
14. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. Chapman J; Geyer JT; Khanlari M; Moul A; Casas C; Connor ST; Fan YS; Watts JM; Swords RT; Vega F; Orazi A Mod Pathol; 2018 Mar; 31(3):429-441. PubMed ID: 29192651 [TBL] [Abstract][Full Text] [Related]
15. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811 [TBL] [Abstract][Full Text] [Related]
16. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia. Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812 [TBL] [Abstract][Full Text] [Related]
18. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270 [TBL] [Abstract][Full Text] [Related]
19. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791 [TBL] [Abstract][Full Text] [Related]
20. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia. Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]